Workshop dates: 1–3 December 2025
Last week (1–3 December 2025), HPA supported the Ministry of Health’s Division of Reproductive, Maternal, Newborn, Child and Adolescent Health (DRMNCAH) to convene a multi‑stakeholder workshop focused on one shared objective: accelerating the inclusion of priority, innovative Maternal and Newborn Health (MNH) products in the KEMSA product listing.
The products reviewed—NASG, Free‑Flow UBT, Calibrated Drapes, Obstetric Point‑of‑Care Ultrasound (OPOCUS), and Haemoglobin Point‑of‑Care devices—are expected to be incorporated into the KEMSA Procurement Plan and, subsequently, featured in KEMSA’s catalogue. This step strengthens availability, standardisation, and sustained access to lifesaving tools across all counties.
HPA was represented by Daniel Menge, who contributed to technical and programmatic discussions covering:
Consensus was also built around enhanced regulatory activities, including import/export controls, support for local production, quality monitoring, and post‑market surveillance—laying the groundwork for safe, reliable scale‑up.
This milestone was possible because of the collaboration and expertise brought by a wide range of partners:
By the close of the workshop, partners aligned on the following deliverables that enable timely procurement and transparent rollout:
This milestone reflects HPA’s continued commitment to maternal wellness, supporting government‑led processes that strengthen the health system while ensuring frontline providers have the right tools at the right time.
HPA extends appreciation to all stakeholders for their leadership and collaboration: